Cross-Talk Between Thyroid Disorders and Nonalcoholic Fatty Liver Disease: From Pathophysiology to Therapeutics

Abstract

The medical community acknowledges the presence of thyroid disorders and nonalcoholic fatty liver disease (NAFLD). Nevertheless, the interconnection between these two circumstances is complex. Thyroid hormones (THs), including triiodothyronine (T3) and thyroxine (T4), and thyroid-stimulating hormone (TSH), are essential for maintaining metabolic balance and controlling the metabolism of lipids and carbohydrates. The therapeutic potential of THs, especially those that target the TRβ receptor isoform, is generating increasing interest. The review explores the pathophysiology of these disorders, specifically examining the impact of THs on the metabolism of lipids in the liver. The purpose of this review is to offer a thorough analysis of the correlation between thyroid disorders and NAFLD, as well as suggest potential therapeutic approaches for the future.

Keywords

thyroid disorders - NAFLD - pathophysiology - therapeutics

Publikationsverlauf

Eingereicht: 16. Dezember 2023

Angenommen nach Revision: 26. Februar 2024

Accepted Manuscript online:
26. Februar 2024

Artikel online veröffentlicht:
05. April 2024

• References

• 1 Wainwright P, Byrne CD. Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome. Int J Mol Sci 2016; 17: 367
• 2 Younossi Z, Anstee QM, Marietti M. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11-20
• 3 Fröhlich E, Wahl R. Insight into potential interactions of thyroid hormones, sex ormones and their stimulating hormones in the development of non-alcoholic fatty liver disease. Metabolites 2022; 12: 718
• 4 Tarantino G, Sinatti G, Citro V. et al. Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression?. Intern Emerg Med 2023; 18: 1887-1895
• 5 Mandato C, D'Acunzo I, Vajro P. Thyroid dysfunction and its role as a risk factor for non-alcoholic fatty liver disease: what's new. Dig Liver Dis 2018; 50: 1163-1165
• 6 Chen J, Wei L, Zhu X. et al. TT3, a more practical indicator for evaluating the relationship between sarcopenia and thyroid hormone in the euthyroid elderly compared with FT3. Clin Interv Aging 2023; 18: 1285-1293
• 7 Chaker L, Bianco AC, Jonklaas J. et al. Hypothyroidism. Lancet 2017; 390: 1550-1562
• 8 Bano A, Chaker L, Plompen EP. et al. Thyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam study. J Clin Endocrinol Metab 2016; 101: 3204-3211
• 9 Xu C, Xu L, Yu C. et al. Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese. Clin Endocrinol (Oxf) 2011; 75: 240-246
• 10 Ludwig U, Holzner D, Denzer C. et al. Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: a cross-sectional study of a random population sample aged 18 to 65 years. BMC Endocr Disord 2015; 15: 41
• 11 Manka P, Bechmann L, Best J. et al. Low free triiodothyronine is associated with advanced fibrosis in patients at high risk for nonalcoholic steatohepatitis. Dig Dis Sci 2019; 64: 2351-2358
• 12 Mantovani A, Nascimbeni F, Lonardo A. et al. Association between primary hypothyroidism and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Thyroid 2018; 28: 1270-1284
• 13 Chung GE, Kim D, Kim W. et al. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol 2012; 57: 150-156
• 14 Martínez-Escudé A, Pera G, Costa-Garrido A. et al. TSH levels as an independent risk factor for NAFLD and liver fibrosis in the general population. J Clin Med 2021; 10: 2907
• 15 Bril F, Kadiyala S, Portillo Sanchez P. et al. Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes. J Investig Med 2016; 64: 63-68
• 16 Lee KW, Bang KB, Rhee EJ. et al. Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: a 4-year retrospective cohort study. Clin Mol Hepatol 2015; 21: 372-378
• 17 Jaruvongvanich V, Sanguankeo A, Upala S. Nonalcoholic fatty liver disease is not associated with thyroid hormone levels and hypothyroidism: a systematic review and meta-analysis. Eur Thyroid J 2017; 6: 208-215
• 18 He W, An X, Li L. et al. Relationship between hypothyroidism and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2017; 8: 335
• 19 Guo Z, Li M, Han B. et al. Association of non-alcoholic fatty liver disease with thyroid function: a systematic review and meta-analysis. Dig Liver Dis 2018; 50: 1153-1162
• 20 Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev 2014; 94: 355-382
• 21 Ritter MJ, Amano I, Hollenberg AN. Thyroid hormone signaling and the liver. Hepatology 2020; 72: 742-752
• 22 Liao CJ, Huang PS, Chien HT. et al. Effects of thyroid hormones on lipid metabolism pathologies in non-alcoholic fatty liver disease. Biomedicines 2022; 10: 1232
• 23 Hammes SR, Davis PJ. Overlapping nongenomic and genomic actions of thyroid hormone and steroids. Best Pract Res Clin Endocrinol Metab 2015; 29: 581-593
• 24 Senese R, Cioffi F, de Lange P. et al. Both 3,5-diiodo-L-thyronine and 3,5,3'-triiodo-L-thyronine prevent short-term hepatic lipid accumulation via distinct mechanisms in rats being fed a high-fat diet. Front Physiol 2017; 8: 706
• 25 Liu YY, Brent GA. Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation. Trends Endocrinol Metab 2010; 21: 166-173
• 26 Berlanga A, Guiu-Jurado E, Porras JA. et al. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 2014; 7: 221-239
• 27 Hashimoto K, Ishida E, Miura A. et al. Human stearoyl-CoA desaturase 1 (SCD-1) gene expression is negatively regulated by thyroid hormone without direct binding of thyroid hormone receptor to the gene promoter. Endocrinology 2013; 154: 537-549
• 28 Sinha RA, Bruinstroop E, Singh BK. et al. Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists. Thyroid 2019; 29: 1173-1191
• 29 Santana-Farré R, Mirecki-Garrido M, Bocos C. et al. Influence of neonatal hypothyroidism on hepatic gene expression and lipid metabolism in adulthood. PLoS One 2012; 7: e37386
• 30 Klieverik LP, Coomans CP, Endert E. et al. Thyroid hormone effects on whole-body energy homeostasis and tissue-specific fatty acid uptake in vivo. Endocrinology 2009; 150: 5639-5648
• 31 Mukhopadhyay D, Plateroti M, Anant S. et al. Thyroid hormone regulates hepatic triglyceride mobilization and apolipoprotein B messenger ribonucleic Acid editing in a murine model of congenital hypothyroidism. Endocrinology 2003; 144: 711-719
• 32 Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol 2018; 14: 259-269
• 33 Perra A, Simbula G, Simbula M. et al. Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. FASEB J 2008; 22: 2981-2989
• 34 Sinha RA, You SH, Zhou J. et al. Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J Clin Invest 2012; 122: 2428-2438
• 35 Sinha RA, Singh BK, Zhou J. et al. Thyroid hormone induction of mitochondrial activity is coupled to mitophagy via ROS-AMPK-ULK1 signaling. Autophagy 2015; 11: 1341-1357
• 36 Singh BK, Sinha RA, Tripathi M. et al. Thyroid hormone receptor and ERRα coordinately regulate mitochondrial fission, mitophagy, biogenesis, and function. Sci Signal 2018; 11: eaam5855
• 37 Weitzel JM, Iwen KA. Coordination of mitochondrial biogenesis by thyroid hormone. Mol Cell Endocrinol 2011; 342: 1-7
• 38 Bruinstroop E, Zhou J, Tripathi M. et al. Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression. Mol Metab 2021; 53: 101266
• 39 Bohinc BN, Michelotti G, Xie G. et al. Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism. Endocrinology 2014; 155: 4591-4601
• 40 Fazaeli M, Khoshdel A, Shafiepour M. et al. The influence of subclinical hypothyroidism on serum lipid profile, PCSK9 levels and CD36 expression on monocytes. Diabetes Metab Syndr 2019; 13: 312-316
• 41 Bonde Y, Breuer O, Lütjohann D. et al. Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. J Lipid Res 2014; 55: 2408-2415
• 42 Ness GC, Pendleton LC, Li YC. et al. Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem Biophys Res Commun 1990; 172: 1150-1156
• 43 Bonde Y, Plösch T, Kuipers F. et al. Stimulation of murine biliary cholesterol secretion by thyroid hormone is dependent on a functional ABCG5/G8 complex. Hepatology 2012; 56: 1828-1837
• 44 Lugari S, Mantovani A, Nascimbeni F. et al. Hypothyroidism and nonalcoholic fatty liver disease – a chance association?. Horm Mol Biol Clin Investig 2018; 41
• 45 Tian L, Song Y, Xing M. et al. A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway. Hepatology 2010; 52: 1401-1409
• 46 Song Y, Xu C, Shao S. et al. Thyroid-stimulating hormone regulates hepatic bile acid homeostasis via SREBP-2/HNF-4α/CYP7A1 axis. J Hepatol 2015; 62: 1171-1179
• 47 Gong Y, Ma Y, Ye Z. et al. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression. Metabolism 2017; 76: 32-41
• 48 Beukhof CM, Massolt ET, Visser TJ. et al. Effects of thyrotropin on peripheral thyroid hormone metabolism and serum lipids. Thyroid 2018; 28: 168-174
• 49 Huang YY, Gusdon AM, Qu S. Cross-talk between the thyroid and liver: a new target for nonalcoholic fatty liver disease treatment. World J Gastroenterol 2013; 19: 8238-8246
• 50 Torun AN, Kulaksizoglu S, Kulaksizoglu M. et al. Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. Clin Endocrinol (Oxf) 2009; 70: 469-474
• 51 Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 370-379
• 52 Kokkinos A, Mourouzis I, Kyriaki D. et al. Possible implications of leptin, adiponectin and ghrelin in the regulation of energy homeostasis by thyroid hormone. Endocrine 2007; 32: 30-32
• 53 Messarah M, Boumendjel A, Chouabia A. et al. Influence of thyroid dysfunction on liver lipid peroxidation and antioxidant status in experimental rats. Exp Toxicol Pathol 2010; 62: 301-310
• 54 Kumar A, Sinha RA, Tiwari M. et al. Hyperthyroidism induces apoptosis in rat liver through activation of death receptor-mediated pathways. J Hepatol 2007; 46: 888-898
• 55 Krause C, Grohs M, El Gammal AT. et al. Reduced expression of thyroid hormone receptor β in human nonalcoholic steatohepatitis. Endocr Connect 2018; 7: 1448-1456
• 56 Liu L, Yu Y, Zhao M. et al. Benefits of levothyroxine replacement therapy on nonalcoholic fatty liver disease in subclinical hypothyroidism patients. Int J Endocrinol 2017; 5753039
• 57 Saponaro F, Sestito S, Runfola M. et al. Selective thyroid hormone receptor-beta (TRβ) agonists: new perspectives for the treatment of metabolic and neurodegenerative disorders. Front Med (Lausanne) 2020; 7: 331
• 58 Araki O, Ying H, Zhu XG. et al. Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms. Mol Endocrinol 2009; 23: 308-315
• 59 Jornayvaz FR, Lee HY, Jurczak MJ. et al. Thyroid hormone receptor-α gene knockout mice are protected from diet-induced hepatic insulin resistance. Endocrinology 2012; 153: 583-591
• 60 Vatner DF, Weismann D, Beddow SA. et al. Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. Am J Physiol Endocrinol Metab 2013; 305: E89-E100
• 61 Puliga E, Min Q, Tao J. et al. Thyroid hormone receptor-β agonist GC-1 inhibits met-β-catenin-driven hepatocellular cancer. Am J Pathol 2017; 187: 2473-2485
• 62 Finan B, Clemmensen C, Zhu Z. et al. Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease. Cell 2016; 167: 843-857.e14
• 63 Erion MD, Cable EE, Ito BR. et al. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci U S A 2007; 104: 15490-15495
• 64 Cable EE, Finn PD, Stebbins JW. et al. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009; 49: 407-417
• 65 Zhou J, Waskowicz LR, Lim A. et al. A liver-specific thyromimetic, VK2809, decreases hepatosteatosis in glycogen storage disease type Ia. Thyroid 2019; 29: 1158-1167
• 66 Loomba R, Neutel J, Mohseni R. et al. LBP-20-VK2809, a novel liver-directed thyroid receptor beta agonist, significantly reduces liver fat with both low and high doses in patients with non-alcoholic fatty liver disease: a phase 2 randomized, placebo-controlled trial. J Hepatol 2019; 70: e150-e151
• 67 Kannt A, Wohlfart P, Madsen AN, Veidal SS. et al. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. Br J Pharmacol 2021; 178: 2412-2423
• 68 Mollica MP, Lionetti L, Moreno M. et al. 3,5-Diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet. J Hepatol 2009; 51: 363-370
• 69 de Lange P, Cioffi F, Senese R. et al. Nonthyrotoxic prevention of diet-induced insulin resistance by 3,5-diiodo-L-thyronine in rats. Diabetes 2011; 60: 2730-2739
• 70 Grasselli E, Voci A, Demori I. et al. 3,5-Diiodo-L-thyronine modulates the expression of genes of lipid metabolism in a rat model of fatty liver. J Endocrinol 2012; 212: 149-158
• 71 Perra A, Kowalik MA, Cabras L. et al. Potential role of two novel agonists of thyroid hormone receptor-β on liver regeneration. Cell Prolif 2020; 53: e12808